ARTICLE
17 February 2022

SQI Diagnostics Completes Acquisition Of Precision Biomonitoring's Human Diagnostic Testing Business

GW
Gowling WLG

Contributor

Gowling WLG is an international law firm built on the belief that the best way to serve clients is to be in tune with their world, aligned with their opportunity and ambitious for their success. Our 1,400+ legal professionals and support teams apply in-depth sector expertise to understand and support our clients’ businesses.
On February 14, 2022, SQI Diagnostics Inc. ("SQI") (TSXV: SQD) (OTCQB: SQIDF) announced that it had completed its previously announced asset acquisition of Precision Biomonitoring
Canada Corporate/Commercial Law

On February 14, 2022, SQI Diagnostics Inc. ("SQI") (TSXV: SQD) (OTCQB: SQIDF) announced that it had completed its previously announced asset acquisition of Precision Biomonitoring Inc.'s ("PBI") human diagnostic COVID-19 PCR testing business and its TripleLock" molecular diagnostic testing technology.

Pursuant to the terms of the definitive agreement, SQI acquired the assets through its wholly owned subsidiary, SQI Diagnostic Systems Inc., for aggregate consideration of $6,825,000 consisting of cash and common shares in the capital of SQI.

Gowling WLG advised PBI with respect to this transaction with a team led by Thomas Hunter and that included Irena Kramer and Michelle Kumar.

Read the original article on GowlingWLG.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More